Heparin and Protamine Sulfate are charged substances which are widely used clinically. Recently it has been appreciated that protamine may cause serious adverse reactions when it is given to reserve the anticoagulant effects of heparin. In the first part of this project, we will examine the mechanism by which protamene may exert these reactions. We will study whether they are due to Type I hypersensitivity and/or whether the effect may be mediated through complement. We will examine the prevalence of positive immediate or delayed skin tests and IgG and IgE anti-protamine in patients who have received protamine containing insulin; in diabetics who have not received protamine containing insulin; in men who have had vasectomy; in other patients who have received protamine; in patients with Type I hypersensitivity to fish; and in a normal population. We will determine the true incidence and the mechanism(s) of hypersensitivity to protamine when the drug is given, to reverse the anticoagulant effect of heparin, to patients who will undergo cardiac catheterization and to patients who will undergo open heart surgery. In the second part of the project, we will examine heparin more fully to determine the Structure Activity Relationship between its fragments and complements. We will study the following polysaccharide mixtures to see which fragments are active in regulating complement: tetrasaccharides, hexasaccharide, octasaccharide, decasaccharide and larger polysaccharides. We will search for heparin fragments of very low MW which have the minimum structure necessary to regulate complement as actively as does commercial heparin. We will examine other heparin-like molecules to determine if they are able to exert the same effects on complement. We will examine other polycations to determine whether they have the same effect. Finally, we will determine if Major Basic Protein, an important constitutent of the eosinophil, may similarly modulate the complement system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI022350-01
Application #
3133310
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1985-09-30
Project End
1988-11-30
Budget Start
1985-09-30
Budget End
1986-11-30
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Caldwell, E E; Nadkarni, V D; Fromm, J R et al. (1996) Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int J Biochem Cell Biol 28:203-16
Booth, B A; Boes, M; Dake, B L et al. (1996) Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3. Growth Regul 6:206-13
Maves, K K; Guenthner, S T; Densen, P et al. (1995) Cloning and characterization of the cDNA encoding guinea-pig properdin: a comparison of properdin from three species. Immunology 86:475-9
Booth, B A; Boes, M; Andress, D L et al. (1995) IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5:1-17
Weiler, J M; Edens, R E; Bell, C S et al. (1995) Eosinophil granule cationic proteins regulate the classical pathway of complement. Immunology 84:213-9
Edens, R E; Fromm, J R; Fromm, S J et al. (1995) Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III. Biochemistry 34:2400-7
Fromm, J R; Hileman, R E; Caldwell, E E et al. (1995) Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys 323:279-87
Bae, J; Desai, U R; Pervin, A et al. (1994) Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J 301 ( Pt 1):121-9
Bittleman, D B; Maves, K K; Bertolatus, J A et al. (1994) Recurrent infections, pericarditis and renal disease in a patient with total C2 deficiency and decreased NK cell function consistent with acute rheumatic fever and systemic lupus erythematosus. Ann Rheum Dis 53:280-1
Edens, R E; Linhardt, R J; Bell, C S et al. (1994) Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27:145-53

Showing the most recent 10 out of 30 publications